Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.

被引：3
|
作者：
Singla, Nirmish [1 ]
Elias, Roy [1 ]
Ghandour, Rashed [1 ]
Freifeld, Yuval N. [1 ]
Bowman, Alex Isaac [1 ]
Woldu, Solomon L. [1 ]
Gahan, Jeffrey [1 ]
Bagrodia, Aditya [1 ]
Brugarolas, James [1 ]
Hammers, Hans J. [1 ]
Margulis, Vitaly [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
619
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Advanced Renal Cell Carcinoma: Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors
    Rini, Brian I.
    ONCOLOGY-NEW YORK, 2022, 36 (08): : 511 - 515
  • [42] SBRT versus nephrectomy in the treatment of renal cell carcinoma.
    Patel, Mausam
    Kim, Thomas
    Li, Chenghui
    Safar, Ahmed
    Maraboyina, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma
    Stuhler, Viktoria
    Rausch, Steffen
    Maas, Jan Moritz
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (09) : 1215 - 1226
  • [44] Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
    Jang, Albert
    Lichterman, Jake N.
    Zhong, Jeffrey Y.
    Shoag, Jonathan E.
    Garcia, Jorge A.
    Zhang, Tian
    Barata, Pedro C.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
  • [45] Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma
    Yuxuan Song
    Yun Peng
    Caipeng Qin
    World Journal of Urology, 2023, 41 : 2301 - 2302
  • [46] Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma
    Song, Yuxuan
    Peng, Yun
    Qin, Caipeng
    WORLD JOURNAL OF UROLOGY, 2023, 41 (08) : 2301 - 2302
  • [47] Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).
    Abou Alaiwi, Sarah
    Martini, Dylan J.
    Xie, Wanling
    Nassar, Amin
    Bakouny, Ziad
    Steinharter, John A.
    Nuzzo, Pier Vitale
    Flippot, Ronan
    Chanza, Nieves M.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Bilen, Mehmet Asim
    Choueiri, Toni K.
    Harshman, Lauren Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors.
    Lee, So Heun
    Park, Inkeun
    Yoon, Shinkyo
    Lee, Jae Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [49] Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
    Kambe, Takanari
    Yamasaki, Toshinari
    Mine, Yuta
    Hagimoto, Hiroki
    Kokubun, Hidetoshi
    Kubota, Masashi
    Tsutsumi, Naofumi
    Inoue, Koji
    Hara, Shigeo
    Kawakita, Mutsushi
    IJU CASE REPORTS, 2022, 5 (03) : 168 - 171
  • [50] Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
    Gul, Anita
    Stewart, Tyler F.
    Mantia, Charlene M.
    Shah, Neil J.
    Gatof, Emily Stern
    Long, Ying
    Allman, Kimberly D.
    Ornstein, Moshe C.
    Hammers, Hans J.
    McDermott, David F.
    Atkins, Michael B.
    Hurwitz, Michael
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3088 - +
12345